Abstract
The objectives of this research work were to develop optimized nanoparticulate formulations of poly (d,l-lactic-co-glycolic acid) (PLGA) (85:15) with an anti-AIDS drug stavudine and to evaluate their in-vitro uptake by the macrophages and hepatotoxicity in-vivo. Nanoparticles were prepared by nanoprecipitation method based on a factorial design with varying parameters such as the amounts of polymer and stabilizer used. Physicochemical characterizations such as drug–excipient interaction, surface morphology, particle size, and zeta potential measurements were carried out. The best formulation was selected and tagged with fluorescein isothiocyanate (FITC) for cellular uptake study of the formulation. In-vitro uptake of nanoparticles by macrophages was carried out. Formulation-induced hepatotoxicity was assessed by analyzing some serum hepatotoxic parameters and hepatic histology following 10-day treatment in comparison with the free drug. Nanoparticles exhibited smooth surface with particle size 84–238 nm, high entrapment efficiency (approx 85%), and negative surface charge. Formulations showed a sustained drug release pattern over the study period. In-vitro uptake study by macrophages exhibited a time-dependent profile. In-vivo studies on rats showed improvement in the serum parameters and maintenance of the integrity of the hepatic architecture indicating decreased hepatotoxicity with the formulations as compared to the free drug. The experimental results showed a positive outcome in the development of antiretroviral drug carrier exhibiting sustained drug release, macrophage-targeted delivery characteristics, and having reduced hepatoxicity. This could be beneficial for the management of early stage of HIV infection besides reducing the drug load for effective treatment, thereby offering an attractive option in AIDS therapy.
Similar content being viewed by others
References
Shi J, Votruba AR, Farokhzad OC, Langer R. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett. 2010;10(9):3223–30.
Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and possibility. J Control Release. 2011;153(3):198–205.
Ramanaa LN, Anand AR, Sethuramana S, Krishnana UM. Targeting strategies for delivery of anti-HIV drugs. J Control Release. 2014;192(10):271–83.
Kraft JC, Freeling JP, Wang Z, Ho RJ. Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. J Pharm Sci. 2014;103(1):29–52.
Ito F, Fujimori H, Makino V. Factors affecting the loading efficiency of water-soluble drugs in PLGA microspheres. Colloids Surf B: Biointerfaces. 2008;61(1):25–9.
Avgoustakis K. Pegylatedpoly(lactide) and poly (lactide-coglycolide) nanoparticles: preparation, properties and possible applications in drug delivery. Curr Drug Deliv. 2004;1(4):321–33.
Barratt GM. Therapeutic applications of colloidal drug carriers: physical structure to therapeutic applications. Pharm Sci Technol Today. 2000;3(5):163–71.
Barlet DW, Davis ME. Physicochemical and biological characterization of targeted nucleic acid-containing nanoparticles. Bioconjug Chem. 2007;18(2):456–68.
Gomes MJ, Neves JD, Sarmento B. Nanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous system. Int J Nanomedicine. 2014;9:1757–69.
Mehta AK, Yadav KS, Sawant KK. Nimodipine loaded PLGA nanoparticles: formulation optimization using factorial design, characterization and in vitro evaluation. Curr Drug Deliv. 2007;4(3):185–93.
Chen X, Young TJ, Sarkari M, Williams RO, Johnston KP. Preparation of cyclosporine A nanoparticles by evaporative precipitation into aqueous solution. Int J Pharm. 2002;242(1–2):3–14.
Anton N, Benoit JP, Saulnier P. Design and production of nanoparticles formulated from nano-emulsion templates—a review. J Control Release. 2008;128(3):185–99.
Barichello JM, Morishita M, Takayama K, Nagai T. Encapsulation of hydrophilic and lipophillic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Dev Ind Pharm. 1999;25(4):471–6.
Bilati U, Allémann E, Doelker E. Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. Eur J Pharm Sci. 2005;24(1):67–75.
Das S, Roy P, Auddy RG, Mukherjee A. Silymarin nanoparticle prevents paracetamol induced hepatotoxicity. Int J Nanomedicine. 2011;6:1291–301.
Govender T, Stolnik S, Garnett MC, Illum L, Davis SS. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release. 1999;57(2):171–85.
Basu S, Mukherjee B, Chowdhury SR, Paul P, Choudhury R, Kumar A, et al. Colloidal gold-loaded, biodegradable, polymer-based stavudine nanoparticles uptake by macrophages: an in vitro study. Int J Nanomedicine. 2012;7:6049–61.
Freeling JP, Koehn J, Shu C, Sun J, Ho RJY. Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates. AIDS Res Hum Retrovir. 2015;31(1):107–14.
Alexaki A, Liu Y, Wigdahl B. Cellular reservoirs of HIV-1 and their role in viral persistence. Curr HIV Res. 2008;6(5):388–400.
Nicholas PK, Kemppainen JK, Canaval GE, Corless IB, Sefcik EF, Nokes KM, et al. Symptom management and self-care for peripheral neuropathy in HIV/AIDS. AIDS Care. 2007;19(2):179–89.
Alimonti JB, Ball TB, Fowke KR. Mechanisms of CD4+ T lymphocyte cell death in human immunodeficiency virus infection and AIDS. J Gen Virol. 2003;84(7):1649–61.
Knoll B, Lassmann B, Temesgen Z. Current status of HIV infection: a review for non HIV treating physicians. Int J Dermatol. 2007;46(12):1219–28.
Edagwa BJ, Zhou T, McMillan JM, Liu XM, Gendelman HE. Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapies. Curr Med Chem. 2014;21(36):4186–98.
Garg M, Dutta T, Jain NK. Reduced hepatic toxicity enhanced cellular uptake and altered pharmacokinetics of stavudine loaded galactosylated liposomes. Eur J Pharm Biopharm. 2007;67(1):76–85.
Bala I, Hariharan S, Kumar R. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst. 2004;21(5):387–422.
Deneka M, Pelchen-Matthews A, Byland R, Ruiz-Mateos E, Marsh M. In macrophages, HIV-1 assembles into an intracellular plasma membrane domain containing the tetraspanins CD81, CD9, and CD53. J Cell Biol. 2007;177(2):329–41.
Maji R, Dey NS, Satapathy BS, Mukherjee B, Mondal S. Preparation and characterization of Tamoxifen citrate loaded nanoparticles for breast cancer therapy. Int J Nanomedicine. 2014;9:3107–18.
Pattnaik G, Sinha B, Mukherjee B, Ghosh S, Basak S, Mondal S, et al. Submicron-size biodegradable polymer-based didanosine particles for treating HIV at early stage: an in vitro study. J Microencapsul. 2012;29(7):666–76.
Roy P, Das S, Bera T, Mondal S, Mukherjee A. Andrographolide nanoparticles in leishmaniasis: characterization and in vitro evaluation. Int J Nanomedicine. 2010;5:1113–21.
Piscitelli SC, Kelly G, Walker RE, Kovacs J, Falloon J, Davey Jr RT, et al. A multiple drug interaction study of stavudine with agents for opportunistic infections in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 1999;43(3):647–50.
Cunha-Filho MS, Martinez-Pacheco R, Landin M. Compatibility of the antitumoral beta lapachone with different solid dosage forms excipients. J Pharm Biomed Anal. 2007;45(4):590–8.
Sahoo SK, Panyam J, Prabha S, Labhasetwar V. Residual polyvinyl alcohol associated with poly (D,L-lactide-coglycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release. 2002;82(1):105–14.
Núñez M. Hepatic toxicity of antiviral agents. In: Kaplowitz N, DeLeve LD, editors. Drug-induced liver disease. Amsterdam: Elsevier; 2013. p. 505–18.
Kim H, Cheng C, Kim Y, Chee Y. Preparation and hydrolytic degradation of semi-interpenetration networks of poly (3-hydroxyundecenoate) and poly(lactide-co-glycolide). Int J Biol Macromol. 2005;37(5):221–6.
Rudra A, Manasadeepa R, Ghosh MK, Ghosh S, Mukherjee B. Doxorubicin-loaded phosphatidylethanolamine-conjugated nanoliposomes: in vitro characterization and their accumulation in liver, kidneys, and lungs in rats. Int J Nanomedicine. 2011;5:811–23.
Mukherjee B, Roy G, Santra K, Sahana K. Lactide-glycolide polymers as nanodimensional carriers of drugs. Int J Biomed Nanosci Nanotechnol. 2010;1(2):230–46.
Mukherjee B, Patra B, Layek B, Mukherjee A. Sustained release of acyclovir from nano-liposomes and nano-niosomes. Int J Nanomedicine. 2007;2(2):213–25.
De S, Robinson DH. Particle size and temperature effect on the physical stability of PLGA nanospheres and microspheres containing Bodipy. AAPS PharmSciTech. 2004;5(4), e53.
Yoo JW, Chambers E, Mitragotri S. Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects. Curr Pharm Des. 2010;16(21):2298–307.
Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med. 1995;1(5):417–22.
Abrescia N, D’Abbraccio M, Figoni M, Busto A, Maddaloni A, De Marco M. Hepatotoxicity of antiretroviral drugs. Curr Pharm Des. 2005;11(28):3697–710.
Spengler U, Lichterfeld M, Rockstroh JK. Antiretroviral drug toxicity—a challenge for the hepatologist? J Hepatol. 2002;36(2):283–94.
Rahman K. Studies on free radicals, antioxidants, and co-factors. Clin Interv Aging. 2007;2(2):219–36.
Acknowledgments
We are indebted to the Indian Council of Medical Research (Grant no 45/6/2013/Nan/BMS) for partially funding the research work.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflicts of interest.
Rights and permissions
About this article
Cite this article
Ghosh, S., Mondal, L., Chakraborty, S. et al. Early Stage HIV Management and Reduction of Stavudine-Induced Hepatotoxicity in Rats by Experimentally Developed Biodegradable Nanoparticles. AAPS PharmSciTech 18, 697–709 (2017). https://doi.org/10.1208/s12249-016-0539-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12249-016-0539-6